Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996283 | 1.00 | MEN1 (0.42) | MEN1GAAKMT2AUSP2SMN1; SMN2 | |
| SCHEMBL1503615 | 0.88 | USP2 (0.41) | MEN1GAAKMT2AUSP2SMN1; SMN2 | |
| SCHEMBL997131 | 0.87 | MEN1 (0.45) | MEN1GAAKMT2ACTSLCTSB | |
| SCHEMBL997132 | 0.87 | MEN1 (0.45) | MEN1GAAKMT2ACTSLCTSB | |
| SCHEMBL996956 | 0.86 | MEN1 (0.44) | MEN1GAAKMT2ACTSLCTSB | |
| SCHEMBL996955 | 0.86 | MEN1 (0.44) | MEN1GAAKMT2ACTSLCTSB | |
| SCHEMBL997414 | 0.86 | MEN1 (0.44) | MEN1GAAKMT2ACTSLCTSB | |
| SCHEMBL31758053 | 0.84 | USP2 (0.45) | MEN1GAAKMT2AUSP2SMN1; SMN2 | |
| SCHEMBL995075 | 0.83 | MEN1 (0.42) | MEN1GAAKMT2ACTSLCTSB | |
| SCHEMBL995076 | 0.83 | MEN1 (0.42) | MEN1GAAKMT2ACTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266848-B2 | 4-alkoxy-N-(2-hydroxycarbamoyl-2-piperidinyl-ethyl)-benzamide compounds as selective TACE-inhibitors for the treatment of inflammatory diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-02-23 | — | — | US | disclosed |
| EP-2448931-B1 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine | GALDERMA RES & DEV (FR) | 2015-05-27 | — | — | EP | disclosed |
| EP-2477969-B1 | 4-ALKOXY-N-(2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL)-BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES. | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-20120226033-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-09-06 | — | — | US | disclosed |
| EP-2477969-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Galderma Research & Development (FR) | 2012-07-25 | — | — | EP | disclosed |
| EP-2448931-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | Galderma Research & Development (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001088-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226033-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | TPSAB1, CTSB, TPSB2 | MEN1 3965/4885GAA 5/4885KMT2A 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.